AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy
Shots:
- AbCellera will receive equity and research fees and is eligible to receive milestone along with royalties based on the development and commercialization of Abs
- Angios gets the rights to develop and commercialize therapeutic products resulting from the collaboration
- AbCellera will use an AI-powered platform to generate panels of Abs for up to three Angios-selected targets against diabetic retinopathy
Ref: BUSINESS WIRE| Image: AbCellera
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
